Teva board agrees with CEO Jeremy Levin's decision to step down

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Teva board agrees with CEO Jeremy Levin's decision to step down

Teva Pharmaceutical Industries ($TEVA) has agreed with Dr. Jeremy Levin that he will step down as president and CEO of the company. The move came amid last week's layoff announcement and an apparent clash between Levin and Teva's board of directors. More

Teva
CEO Jeremy Levin has stepped down.


Johnson & Johnson
Alison Lewis will become the first-ever global chief marketing officer for J&J's consumer companies.


Biotech

Advaxis ($ADXS) appointed Gregory Mayes as its chief operating officer, following a position at Dendreon ($DNDN) as executive vice president of human resources. Release

> Dr. Nancy Lynch joined Histogenics as the company's chief medical officer. Release

CytoDyn brought on Dr. David Feigal, a former FDA leader, as its chief medical officer. Release

Arcturus Therapeutics appointed Zachary Zimmerman as its chief business officer. Zimmerman has specialized in the RNA field before at both Alnylam ($ALNY) and Regulus ($RGLS). Release

Lorus Therapeutics brought on William Rice as the company's CEO. Rice was formerly CEO of Cylene Pharmaceuticals. Release

John Eppig, a professor at the Jackson Laboratory since 1975, was elected to the National Academy of Sciences. Release

IntelliCell BioSciences appointed Michael Herschman as the chairman of its board of directors. Release

Paul Yaswen joined Iris BioTechnologies as the company's chief scientific officer. Release

Tassos Gianakakos has joined MyoKardia as CEO. Gianakakos, who most recently served as senior vice president and chief business officer at MAP Pharmaceuticals ($MAPP), succeeds founding CEO Dr. Charles Homcy, who will remain on MyoKardia's board of directors. Release

Dr. Jose Baselga has been named senior medical adviser to Verastem ($VSTM). Baselga is physician-in-chief at Memorial Sloan-Kettering Cancer Center. Release

Gary O'Neill has joined Abide Therapeutics as vice president of biology and a member of the senior management team. O'Neill was previously with Merck ($MRK), where he led preclinical drug discovery programs in the respiratory, immunology and oncology disease areas. Release

PrognosDx Health has appointed Joseph Vallner, formerly president and chief operating officer at Cell Genesys ($CEGE), as the company's new CEO. Release

Pharma

Johnson & Johnson ($JNJ) has tapped Alison Lewis, CocaCola's head marketer in North America, as the pharma giant's first-ever global chief marketing officer of its consumer companies. More

Astellas Pharma brought on Jeffrey Winton as the company's senior vice president and chief communications officer. Release

Dr. John Nicholson, a cardiologist and clinical associate professor at Cornell University, has been appointed to Pivotal Therapeutics' board of directors. Release

Furiex Pharmaceuticals ($FURX) has appointed Sailash Patel to the position of chief financial officer. Patel has been with Furiex since its spin-off from PPD and currently serves as vice president of strategic development. Release

AMAG Pharmaceuticals ($AMAG) has appointed Dr. Robert F. Kaper to the role of senior vice president of medical and scientific affairs. Release

CRO

Richard Segiel, Jr., has joined Almac Group as vice president of business development for the U.S. Most recently, Segiel served as business development director of Intertek Pharmaceutical Services. Release 

Pharma Manufacturing

Cambridge Major Laboratories and AAIPharma Services have appointed Patrick Walsh CEO of the merged company. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.